Skip Navigation

Health: HIV/AIDS

Opinions

  • Print
  • Comment
  • | Share

Development of a marketable AIDS vaccine uncertain

Source: New England Journal of Medicine

28 December 2007 | EN | 中文

A quarter century after a United States health official said there would be a marketable AIDS vaccine within "a minimum of two years", we must face the possibility that it may never happen.

Global investment in HIV vaccine research and development stands at US$759 million, quotes Robert Steinbrook in the New England Journal of Medicine

But he notes that a series of unsuccessful trials has reinforced the view that a licensed AIDS vaccine is at least a decade away — and that is "if things go well".

Steinbrook points out that the sole large-scale study of an AIDS vaccine, in Thailand, is currently underway and is expected to continue until 2009.

He says the scientific challenges blocking progress on a vaccine include the genetic diversity and rapid changes of the viral envelope proteins and incomplete understanding of critical immune responses that would prevent infection or control the virus.

Anthony Fauci, the director of the US National Institute for Allergy and Infectious Diseases, is quoted as saying, "We have to leave open the possibility...that we might not ever get a vaccine for HIV.…We are not giving up...but there is a possibility — a clear finite possibility — that that's the case."

Link to full article in the New England Journal of Medicine

Add your comment

This is your network: share your views on any of our articles by adding your comments.

You need to be signed in to post a comment or to email a consenting comment author. Please sign in or sign up.

All comments are subject to approval and we reserve the right to edit comments containing inappropriate/unsuitable language. SciDev.Net holds copyright for all material posted on the website. Please see terms of use for further details.

All SciDev.Net material is free to reproduce providing that the source and author are appropriately credited. For further details see Creative Commons.

Back to Opinions
To the top